|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0030705,
umls-concept:C0036525,
umls-concept:C0205195,
umls-concept:C0205369,
umls-concept:C0217843,
umls-concept:C0231491,
umls-concept:C0246415,
umls-concept:C0376358,
umls-concept:C0439611,
umls-concept:C1522484,
umls-concept:C2603343,
umls-concept:C2713006
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2011-7-25
|
|
pubmed:abstractText |
This two-part study assessed the safety and tolerability of combined treatment with zibotentan (ZD4054), a specific endothelin A receptor antagonist, plus docetaxel in patients with metastatic castration-resistant prostate cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1097-0045
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2011 Wiley-Liss, Inc.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
71
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1264-75
|
|
pubmed:meshHeading |
pubmed-meshheading:21271613-Adenocarcinoma,
pubmed-meshheading:21271613-Aged,
pubmed-meshheading:21271613-Aged, 80 and over,
pubmed-meshheading:21271613-Antineoplastic Agents,
pubmed-meshheading:21271613-Bone Neoplasms,
pubmed-meshheading:21271613-Cohort Studies,
pubmed-meshheading:21271613-Dose-Response Relationship, Drug,
pubmed-meshheading:21271613-Double-Blind Method,
pubmed-meshheading:21271613-Drug Therapy, Combination,
pubmed-meshheading:21271613-Humans,
pubmed-meshheading:21271613-Leukopenia,
pubmed-meshheading:21271613-Male,
pubmed-meshheading:21271613-Middle Aged,
pubmed-meshheading:21271613-Neutropenia,
pubmed-meshheading:21271613-Orchiectomy,
pubmed-meshheading:21271613-Pain,
pubmed-meshheading:21271613-Prostatic Neoplasms,
pubmed-meshheading:21271613-Pyrrolidines,
pubmed-meshheading:21271613-Receptor, Endothelin A,
pubmed-meshheading:21271613-Taxoids,
pubmed-meshheading:21271613-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.
|
|
pubmed:affiliation |
Roswell Park Cancer Institute, Buffalo, NY, USA. donald.trump@roswellpark.org
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
